UK-based particle engineering specialist Micropore Technologies has announced a License Agreement with South Korea based G2GBIO Inc. to deploy its patented membrane technology, for the manufacture of G2GBIO’s sustained release pharmaceutical products.
 
G2GBIO specializes in the development of long-acting microsphere products. Micropore’s membrane-based encapsulation system will complement G2GBIO’s existing InnoLAMP technology for the manufacture of monodisperse microspheres composed of various polymers for long-acting drugs for the treatment of various medical conditions such as central nervous system diseases, including dementia or schizophrenia, and chronic diseases, such as cancer and diabetes.
 
Scaling Up Production
 
Micropore’s patented high-throughput membrane encapsulation technology will allow G2GBIO to further scale up GMP production of its encapsulated products enabling the manufacture of 1kg/hour of emulsion with precisely uniform particle sizes. This throughput equates to 1,000 vials for Alzheimer’s disease treatment or about 30,000 vials for animal neutering drugs. According to G2G Bio, no other company in South Korea can currently achieve these scales of production.
 
Because Micropore’s patented technology is based on a crossflow technique utilizing tubular membranes, with no moving parts, when it comes to manufacturing microcapsules the minimal shear forces involved protects sensitive ingredients from processing damage – significantly reducing wastage. Micropore’s equipment also reduces processing energy by around a 30% – again contributing a positive impact on the end cost of drug products.
 
This news follows an announcement earlier this year of a similar licensing agreement between Micropore Technologies and Netherlands-based pharmaceutical producer InnoCore Technologies.